Cargando…

Androgen receptor expression on circulating tumor cells in metastatic breast cancer

PURPOSE: Androgen receptor (AR) is frequently detected in breast cancers, and AR-targeted therapies are showing activity in AR-positive (AR+) breast cancer. However, the role of AR in breast cancers is still not fully elucidated and the biology of AR in breast cancer remains incompletely understood....

Descripción completa

Detalles Bibliográficos
Autores principales:	Fujii, Takeo, Reuben, James M., Huo, Lei, Espinosa Fernandez, Jose Rodrigo, Gong, Yun, Krupa, Rachel, Suraneni, Mahipal V., Graf, Ryon P., Lee, Jerry, Greene, Stephanie, Rodriguez, Angel, Dugan, Lyndsey, Louw, Jessica, Lim, Bora, Barcenas, Carlos H., Marx, Angela N., Tripathy, Debu, Wang, Yipeng, Landers, Mark, Dittamore, Ryan, Ueno, Naoto T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5619732/ https://www.ncbi.nlm.nih.gov/pubmed/28957377 http://dx.doi.org/10.1371/journal.pone.0185231

Ejemplares similares

Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients
por: Anantharaman, Archana, et al.
Publicado: (2016)

Analytical Validation and Capabilities of the Epic CTC Platform: Enrichment-Free Circulating Tumour Cell Detection and Characterization
por: Werner, Shannon L., et al.
Publicado: (2015)

Chromosomal Instability Estimation Based on Next Generation Sequencing and Single Cell Genome Wide Copy Number Variation Analysis
por: Greene, Stephanie B., et al.
Publicado: (2016)

EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream(®) in patients with breast cancer treated with primary systemic therapy
por: Le Du, Fanny, et al.
Publicado: (2020)

Detection and Characterization of Circulating Tumour Cells from Frozen Peripheral Blood Mononuclear Cells
por: Lu, David, et al.
Publicado: (2015)

Location of Receipt of Initial Treatment and Outcomes in Long-Term Breast Cancer Survivors
por: Sinha, Arup K., et al.
Publicado: (2017)

Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis
por: Kono, Miho, et al.
Publicado: (2018)

Phase II study of Radium‐223 dichloride combined with hormonal therapy for hormone receptor‐positive, bone‐dominant metastatic breast cancer
por: Ueno, Naoto T., et al.
Publicado: (2019)

Reply to ‘Comment on ‘Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy''
por: Fujii, Takeo, et al.
Publicado: (2017)

PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening
por: Lee, Jangsoon, et al.
Publicado: (2021)

Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy
por: Fujii, Takeo, et al.
Publicado: (2017)

Reverse phase protein array identification of triple-negative breast cancer subtypes and comparison with mRNA molecular subtypes
por: Masuda, Hiroko, et al.
Publicado: (2017)

Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines
por: Xie, Xuemei, et al.
Publicado: (2023)

HER2 status and breast cancer therapy: recent advances
por: Tripathy, Debu
Publicado: (2009)

The BMC Medicine breast cancer collection: an illustration of contemporary research and clinical care
por: Tripathy, Debu
Publicado: (2015)

Validation of Prognostic Stage and Anatomic Stage in the American Joint Committee on Cancer 8th Edition for Inflammatory Breast Cancer
por: Kida, Kumiko, et al.
Publicado: (2020)

The impact of Ki-67 in the context of multidisciplinary care in primary inflammatory breast cancer
por: Ning, Jing, et al.
Publicado: (2019)

NDRG1 Expression Is an Independent Prognostic Factor in Inflammatory Breast Cancer
por: Villodre, Emilly S., et al.
Publicado: (2020)

Prognostic Model for De Novo and Recurrent Metastatic Breast Cancer
por: Barcenas, Carlos H., et al.
Publicado: (2021)

Reassessing Estrogen Receptor Expression Thresholds for Breast Cancer Prognosis in HER2-negative Patients Using Shape Restricted Modeling
por: Dong, Wenli, et al.
Publicado: (2023)

Tumor-suppressive functions of 15-Lipoxygenase-2 and RB1CC1 in prostate cancer
por: Suraneni, Mahipal V, et al.
Publicado: (2014)

OR30-5 Androgen-Regulated Secreted Factors Promote Tumorigenesis and Immune Suppression in Breast Cancer
por: Richer, Jennifer, et al.
Publicado: (2022)

A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment
por: Lim, Bora, et al.
Publicado: (2019)

Pituitary Androgen Receptor Signalling Regulates Prolactin but Not Gonadotrophins in the Male Mouse
por: O’Hara, Laura, et al.
Publicado: (2015)

Simulating androgen receptor selection in designer yeast
por: Zhang, Haoran, et al.
Publicado: (2022)

Decorin-mediated suppression of tumorigenesis, invasion, and metastasis in inflammatory breast cancer
por: Hu, Xiaoding, et al.
Publicado: (2021)

Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies
por: Zurita, Amado J., et al.
Publicado: (2022)

EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer
por: Wang, Xiaoping, et al.
Publicado: (2017)

Incorporation of clinical and biological factors improves prognostication and reflects contemporary clinical practice
por: Murthy, Rashmi K., et al.
Publicado: (2020)

In vivo functional studies of tumor-specific retrogene NanogP8 in transgenic animals
por: Badeaux, Mark A, et al.
Publicado: (2013)

Influencers of the Decision to Undergo Contralateral Prophylactic Mastectomy among Women with Unilateral Breast Cancer
por: Singareeka Raghavendra, Akshara, et al.
Publicado: (2021)

The Impact of Treatment for Smoking on Breast Cancer Patients’ Survival
por: Singareeka Raghavendra, Akshara, et al.
Publicado: (2022)

Next generation sequencing and tumor mutation profiling: are we ready for routine use in the oncology clinic?
por: Tripathy, Debu, et al.
Publicado: (2014)

In an Ovine Model of Polycystic Ovary Syndrome (PCOS) Prenatal Androgens Suppress Female Fetal Renal Gluconeogenesis
por: Connolly, Fiona, et al.
Publicado: (2015)

A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer
por: Kai, Megumi, et al.
Publicado: (2021)

Anogenital Distance Plasticity in Adulthood: Implications for Its Use as a Biomarker of Fetal Androgen Action
por: Mitchell, Rod T., et al.
Publicado: (2015)

Association of Copy Number Variation Signature and Survival in Patients With Serous Ovarian Cancer
por: Graf, Ryon P., et al.
Publicado: (2021)

BRAF V600E and RNF43 Co-mutations Predict Patient Outcomes with Targeted Therapies in Real-World Cases of Colorectal Cancer
por: Quintanilha, Julia C F, et al.
Publicado: (2023)

Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer
por: Arango, Natalia Paez, et al.
Publicado: (2017)

A randomised controlled trial of ‘clockwise’ ultrasound for low back pain
por: Louw, Adriaan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_kumjuovger7afqnceh8q7jggcv